An experimental anti-platelet compound inhibited clot formation without increasing bleeding, a common and potentially dangerous side effect of current anti-clotting therapies, according to new phase I research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal. The results of the industry-sponsored trial are based on a first-in-human study of the new compound called ACT017 . The findings suggest that the drug may provide an effective and safer alternative to current anti-platelet therapies used in stroke patients, which can also increase the risk for dangerous bleeding in the brain.
"There is a clear need for a novel anti-platelet agent that resolves platelet aggregation and clot formation without raising the risk for bleeding. Such a therapy would considerably improve and expand our current therapeutic arsenal for the treatment of acute stroke,"…
